Skip to content
HowShorted

Dyne Therapeutics, Inc. short interest in 2023

In 2023, Dyne Therapeutics, Inc.'s disclosed short interest ran from 5.45% of shares outstanding on 13 Jan 2023 to 15.93% on 29 Dec 2023, a change of +10.48 percentage points. The year's high was 15.93% on 29 Dec 2023 and its low 5.45% on 13 Jan 2023, averaging 9.63% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 22.41 days on 28 Apr 2023. Full history: Dyne Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Dyne Therapeutics, Inc. in 2023

2023 in figures

Start of year
5.45% (13 Jan 2023)
End of year
15.93% (29 Dec 2023)
Change
+10.48 pp
High
15.93% (29 Dec 2023)
Low
5.45% (13 Jan 2023)
Average
9.63%
Highest days to cover
22.41 (28 Apr 2023)
SEC filings marked
8

Every report in 2023

Dyne Therapeutics, Inc. short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 20235.45%8.19
31 Jan 20236.82%12.81
15 Feb 20237.09%14.28
28 Feb 20237.24%15.79
15 Mar 20237.81%16.4510-K filed, results (8-K)
31 Mar 20238.22%8.89
14 Apr 20239.36%10.30
28 Apr 20239.37%22.41
15 May 20238.56%8.4610-Q filed, results (8-K)
31 May 20238.48%14.97
15 Jun 20238.36%9.88
30 Jun 20239.39%4.63
14 Jul 20239.29%14.34
31 Jul 20238.51%13.63
15 Aug 20239.34%18.3010-Q filed, results (8-K)
31 Aug 20239.22%18.05
15 Sep 20239.01%9.42
29 Sep 20239.62%10.17
13 Oct 202310.11%13.47
31 Oct 202311.69%12.2010-Q filed, results (8-K)
15 Nov 202312.15%11.15
30 Nov 202314.16%11.70
15 Dec 202315.85%12.64
29 Dec 202315.93%15.94

See also: Dyne Therapeutics, Inc.'s full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.